Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Friday. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Trading Up 1.8 %

Shares of CTSO opened at $0.94 on Friday. The firm’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.02. The stock has a market cap of $51.21 million, a PE ratio of -2.60 and a beta of 0.58. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.59.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently modified their holdings of CTSO. Atomi Financial Group Inc. purchased a new position in Cytosorbents during the third quarter worth about $51,000. Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.